Latest Articles

Publication Date
Optimal management of large endometriomas (≥ 4 cm) before IVF: ethanol sclerotherapy, cystectomy, or no intervention?

The optimal management strategy for large (≥ 4 cm) endometriomas prior to in vitro fertilization (IVF) remains uncertain. This study aimed to compare the cumulative live birth rate (CLBR) among …

Published: Oct. 21, 2025, midnight
Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.

Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age. It commonly presents with pelvic pain, dysmenorrhea, and infertility, imposing substantial physical, psychological, and social burdens. …

Published: Oct. 21, 2025, midnight
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage.

Endometriosis (EMs) and recurrent miscarriage (RM) represent major reproductive health challenges. This study investigates the involvement of endothelial-mesenchymal transition (EndMT) in these conditions through integrative bioinformatics analysis, focusing on the …

Published: Oct. 21, 2025, midnight
Mediterranean diet adherence and healthy diet indicator might decrease odds of endometriosis.

Diet may play a crucial role in managing endometriosis. Dietary interventions could help women with endometriosis improve their quality of life and reduce pain symptoms. The aim of this study …

Published: Oct. 21, 2025, midnight
Pro-endometriosis macrophage release of IL-33 is key for endometriosis pain and lesion formation.

Endometriosis is a painful gynecological inflammatory disease affecting up to 10% of females. When released by sensory neurons, calcitonin gene-related peptide (CGRP) shapes immunity, a process known as neuroimmune communication. …

Published: Oct. 21, 2025, midnight
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO - Citeline News & Insights

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO Citeline News & Insights

Published: Oct. 20, 2025, 10:35 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 20, 2025, 9:33 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0

Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0

Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com

Published: Oct. 20, 2025, 3:02 p.m.
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU - The Manila Times

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU The Manila Times

Published: Oct. 20, 2025, 12:36 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!